Clinical Trial

Talazoparib/Enzalutamide or Enzalutamide in Prostate Cancer

Study Description

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Talazoparib with enzalutamide

Talazoparib 0.5 mg/day plus enzalutamide 160mg/day

Drug - Placebo with enzalutamide

Placebo plus enzalutamide 160 mg/day

Additional Information

Official Study Title

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Clinical Trial ID

NCT03395197

ParticipAid ID

Xe0GVd